Amgen 2013 Annual Report Download - page 49
Download and view the complete annual report
Please find page 49 of the 2013 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39 -
40 -
41 -
42 -
43 -
44 -
45 -
46 -
47 -
48 -
49 -
50 -
51 -
52 -
53 -
54 -
55 -
56 -
57 -
58 -
59 -
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
-
183
-
184
-
185
-
186
-
187
-
188
-
189
-
190
-
191
-
192
-
193
-
194
-
195
-
196
-
197
-
198
-
199
-
200
-
201
-
202
-
203
-
204
-
205
-
206
-
207
 |
 |
The decreases in U.S. Aranesp ® sales for both 2013 and 2012 were driven by declines in unit demand. The unit declines reflect changes in practice
patterns resulting from changes to the label and to the reimbursement environment that occurred during 2011.
The decrease in ROW Aranesp ® sales for 2013 reflects unit declines and price pressure in Europe. In 2012, the ROW decline was driven by a decrease
in the average net sales price.
EPOGEN®
Total EPOGEN® sales were as follows (dollar amounts in millions):
EPOGEN® — U.S. $1,953
1%
$1,941
(5)%
$2,040
EPOGEN® sales for 2013 increased by 1% due to unit growth.
The decrease in EPOGEN® sales for 2012 was driven by a 23% decrease in unit demand, driven by reductions in dose utilization due to changes to the
label and to the reimbursement environment that occurred in 2011. This decrease was offset partially by reductions in customer discounts, as part of new
provider contracts that became effective January 1, 2012, and by a year-over-year favorable change in accounting estimates of $96 million.
Future EPOGEN® sales will also depend, in part, on such factors as:
•response to changes in reimbursement including recent reduction to the ESRD payment bundle effective January 1, 2014;
•potential increased competition in the U.S. dialysis setting; and
•changes in dose utilization as healthcare providers continue to refine their treatment practices in accordance with approved labeling.
See Item 1. Business — Marketing, Distribution and Selected Marketed Products — Competition.
XGEVA® and Prolia®
Total XGEVA
® and total Prolia® sales by geographic region were as follows (dollar amounts in millions):
XGEVA® — U.S. $ 764
19%
$644
88%
$343
XGEVA® — ROW 255
*
104
*
8
Total XGEVA
®1,019
36%
748 *
351
Prolia® — U.S. 462
58%
292
*
130
Prolia® — ROW 282
57%
180
*
73
Total Prolia®744
58%
472
*
203
Total XGEVA
®/Prolia®$1,763
45%
$ 1,220
*
$554
* Change in excess of 100%
The increases in global XGEVA® and Prolia® sales for 2013 and 2012 were driven primarily by unit growth.
Sequentially, global XGEVA® and Prolia® sales increased 10% and 33%, respectively, in the quarter ended December 31, 2013, compared with the
quarter ended September 30, 2013.
In 2013, XGEVA® was launched in several additional countries including France and Spain and is now available in all major markets. XGEVA ® also
faces increased competition. See Item 1. Business — Marketing, Distribution and Selected Marketed Products — Competition.
43